SG&A Expense Trends: MorphoSys AG vs ImmunityBio, Inc.

In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of MorphoSys AG and ImmunityBio, Inc. from 2014 to 2023. Over this period, ImmunityBio, Inc. exhibited a remarkable 2,900% increase in SG&A expenses, peaking in 2015. Meanwhile, MorphoSys AG's expenses grew by approximately 850%, with a notable spike in 2020.

Key Insights

• ImmunityBio, Inc.: The company's SG&A expenses surged dramatically in 2015, reaching their highest point, before stabilizing in subsequent years.
• MorphoSys AG: Experienced a steady increase, with a significant rise in 2020, reflecting strategic investments.

These trends highlight the dynamic nature of financial management in biotech firms, where strategic spending can drive growth and innovation. Understanding these patterns offers valuable insights for investors and industry analysts.